Skip to main
MYO

Myomo (MYO) Stock Forecast & Price Target

Myomo (MYO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Myomo Inc. has demonstrated a significant increase in its reimbursement pipeline, growing from 1,389 units in Q4 to 1,669 in the most recent quarter, indicating strong demand for its myoelectric orthosis products. The company is poised for enhanced revenue growth, as approximately 22% of its projected revenue in 2024 is anticipated to come from orthotics and prosthetics providers, while also redirecting its focus towards the extensive Medicare market. Additionally, the favorable ruling from the Centers for Medicare & Medicaid Services (CMS) in March 2024, which includes MyoPro in Medicare Part B benefits, substantially expands the accessible market and strengthens Myomo's competitive positioning.

Bears say

Myomo Inc. has recently lowered its guidance for 2025 revenue expectations to a range of $40 – 42 million, down from a prior estimate of $50 – 53 million, indicating potential financial difficulties ahead. The company is also experiencing challenges with its marketing efforts, resulting in poorer lead quality and pipeline conversions, which are essential for sustaining revenue growth. Additionally, the decrease in the backlog of authorized insurance claims, from 272 in Q4 to 208, underscores a declining demand for its products that could further exacerbate the company's financial outlook.

Myomo (MYO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myomo (MYO) Forecast

Analysts have given Myomo (MYO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Myomo (MYO) has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myomo (MYO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.